Compare McCormick & Company, Incorporated (MKC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Summit Therapeutics Inc — how do they compare? McCormick & Company, Incorporated trades at $52.01 (market cap $14.04B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: McCormick & Company, Incorporated is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MKC | SMMT | |
|---|---|---|
Market Cap | $14.04B | $10.48B |
Sector | Consumer Staples | Health |
52-Week High | $72.81 | $29.32 |
52-Week Low | $45.60 | $13.05 |
Enterprise Value | $18.65B | $9.90B |
Dividend Yield | 3.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $52.35, up 1.26% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 21.91% net margin and 25.7% ROE, supported by recent Q2 2026 earnings beating estimates. Valuation appears attractive with a P/E of 8.69 and P/S of 1.9. The pending Unilever Foods deal, highlighted in recent news (The Motley Fool, 2026-07-07), could transform the business, though organic growth remains modest.
The outlook is cautiously optimistic with 36.7% of analysts rating it Buy and a consensus price target of $59.67 (13.9% upside). Key risks include soft consumer volumes and execution challenges from the Unilever integration. Positive cash flow projections for 2026 and a sustainable dividend enhance appeal, but investors should monitor volume trends and deal progress closely.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
